文摘
摘要目的:我们的研究的目的是评估的潜在生物标记物持续的高血压脑出血患者(HTN)(我)。
背景:我复发HTN是一种可改变的危险因素和影响超过80%的患者我;然而,只有不到40%的患者达到英国石油公司控制。高醛甾酮症HTN的可能是一个诊断的原因,可能作为一种生物标志物的持久HTN我人口。
设计/方法:减少试验是一个持续的、多中心、非盲、随机临床试验比较标准HTN方案和spironolactone-containing方案我幸存者。基线电解质,醛固酮水平,血浆肾素活性和串行直立BP随机化前测量得到。患者平均收缩压≥120毫米汞柱被随机分配。我们评估是否醛固酮和血浆肾素活性可以预测持续HTN在这些病人。低醛固酮被定义为< 2毫微克/分升和低血浆肾素活性被定义为< 0.7 ng / mL /人力资源。
结果:迄今为止,33名患者已经在减少(76%为男性,平均年龄:62),其中76%是随机的(平均BP药物pre-randomization: 3)。患者低醛固酮(< 2 ng / dL) (n = 10)不太可能平均post-ICH收缩期BPs≥120毫米汞柱(χ2= 9.99,p = 0.002)。患者醛固酮水平≥2毫微克/分升(n = 23)患者平均收缩压135毫米汞柱,醛固酮水平较低(< 2 ng / dL) (n = 10)平均118毫米汞柱的收缩压(p = 0.003)。醛固酮升高仍密切相关,其收缩压在控制了年龄和性别(或= 16.52,95%可信区间(1.94 - -140.87),p = 0.01)。血浆肾素活性与收缩压无关(p = 0.437)。
结论:这初步的数据减少试验指出,醛固酮作为潜在生物标志物预测我患者收缩压升高。
披露:Zabinska女士没有披露。彭博士没有披露。福尔曼博士没有披露。施瓦茨女士没有披露。酒店现有女士没有披露。阿迈女士没有披露。博士的机构要求已经收到NIH的研究支持。制度的要求博士接到啊哈研究支持。博士德Havenon已收到个人薪酬在500 - 4999美元的范围为Integra担任顾问。博士德Havenon Certus股票。 The institution of Dr. De Havenon has received research support from NIH/NINDS. The institution of Dr. De Havenon has received research support from Regeneron Pharmaceuticals. The institution of Dr. De Havenon has received research support from AMAG Pharmaceuticals. The institution of Dr. De Havenon has received research support from AMGEN. Dr. De Havenon has received publishing royalties from a publication relating to health care. Dr. Sansing has nothing to disclose. Mr. Lalwani has nothing to disclose. Ms. Parasuram has nothing to disclose. Miss Yadlapalli has nothing to disclose. Dr. Bushnell has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ZZ Biotech. The institution of Dr. Bushnell has received research support from PCORI. The institution of Dr. Bushnell has received research support from AHRQ. The institution of Dr. Bushnell has received research support from NIH/NINDS. Dr. Bushnell has received intellectual property interests from a discovery or technology relating to health care. Dr. Bushnell has received publishing royalties from a publication relating to health care. Dr. Mullen has received publishing royalties from a publication relating to health care. Jordana Cohen has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wiley Online Library (Pharmacoepidemiology and Drug Safety). The institution of Jordana Cohen has received research support from NIH-NHLBI. An immediate family member of DEBBIE Cohen has received stock or an ownership interest from incyte. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novo Nordisk. Dr. Messe has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Terumo. The institution of Dr. Messe has received research support from WL Gore. The institution of Dr. Messe has received research support from Novartis. The institution of Dr. Messe has received research support from Mallinkrodt. The institution of Dr. Messe has received research support from Biogen. Dr. Messe has received intellectual property interests from a discovery or technology relating to health care. Dr. Messe has received publishing royalties from a publication relating to health care. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.
